Combination of the DOPA decarboxylase inhibitor benserazide and levodopa used for the treatment of Parkinsons disease. The ratio developed when levodopa was shown to be correct in most clinical practice by the end of the 1970s and is regarded by most as therapeutically equivalent to co-careldopa at equivalent levodopa dose.
- ↑ Rinne UK, Mölsä P. Levodopa with benserazide or carbidopa in Parkinson disease. Neurology. 1979 Dec; 29(12):1584-1589.(Print) (Link to article – subscription may be required.)
- ↑ Pakkenberg H, Birket-Smith E, Dupont E, Hansen E, Mikkelsen B, Presthus J, Rautakorpi I, Riman E, Rinne UK. Parkinson's disease treated with Sinemet or Madopar. A controlled multicenter trial. Acta neurologica Scandinavica. 1976 May; 53(5):376-385.(Print) (Link to article – subscription may be required.)
- ↑ Greenacre JK, Coxon A, Petrie A, Reid JL. Comparison of levodopa with carbidopa or benserazide in parkinsonism. Lancet (London, England). 1976 Aug; 2(7982):381-384.(Print) (Link to article – subscription may be required.)